Oncology News

WASHINGTON — Fewer Black and Hispanic patients received curative treatment for early-stage hepatocellular carcinoma compared with white patients, according to research presented at The Liver Meeting.

WASHINGTON — The MELD score at transplant minus three points policy led to poor survival and recurrence outcomes after liver transplantation among patients with hepatocellular carcinoma, according to research at The Liver Meeting.

The FDA granted orphan drug designation to OTX-2002 for the treatment of hepatocellular carcinoma, according to the agent’s manufacturer.

The FDA approved tremelimumab in combination with durvalumab for adults with unresectable hepatocellular carcinoma.

Second- and third-generation individuals of Mexican descent who reside in the U.S. had a higher risk for developing hepatocellular carcinoma than first-generation U.S. Mexicans, according to study results.

Investigators have identified an elevated risk for hepatocellular carcinoma in people exposed to per- and polyfluoroalkyl substances, according to a study published in JHEP Reports.

Researchers reported excellent 10-year outcomes among patients with hepatocellular carcinoma that was downstaged to within Milan criteria prior to liver transplant, according to a multicenter analysis published in JAMA Surgery.

Despite global declines in liver cancer mortality attributed to hepatitis B and C, liver cancer mortality rose sharply in the Americas, driven by an increase in nonalcoholic steatohepatitis, according to data published in Cell Metabolism.

Hepatocellular carcinoma surveillance was underutilized in more than 80% of patients with cirrhosis, with lack of clinician orders and lack of patient adherence cited as common screening barriers, according to a study in JAMA Network Open.

There was no clinically meaningful difference in the risk for hepatocellular carcinoma between patients taking tenofovir vs. entecavir to treat chronic hepatitis B virus infection, according to study results published in JAMA Network Open.